BBNX Beta Bionics, Inc.
Beta Bionics, Inc. (BBNX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 86% planned / 14% discretionary
Largest single sale: $58.3K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Feider Stephen | Chief Financial Officer | Sell 10b5-1 | 382 | $17.04 | $6.5K | 159,378 −0.2% of holding | |
| Mensinger Mike | Chief Product Officer | Sell 10b5-1 | 2,650 | $22.00 | $58.3K | 174,740 −1.5% of holding | |
| Hopman Mark | Chief Commercial Officer | Sell 10b5-1 | 821 | $20.00 | $16.4K | 54,513 −1.5% of holding | |
| Hopman Mark | Chief Commercial Officer | Sell | 775 | $17.35 | $13.4K | 55,334 −1.4% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.